HAE International is offering free, online advocacy courses. This extremely comprehensive program is designed to support people with HAE in everyday life. The courses are delivered in small manageable chunks and can be accessed at any time, from anywhere
Please join us on Saturday November 20th from 1:00-3:00pm ET for our next Update! Details can also be found on our Upcoming Events page.
We hope you can join us for our 2021 AGM. Please check your inbox for the invitation and links to register. Please check your spam box if you do not receive our invitation - unfortunately
Please mark your calendars! HAE Canada is hosting a Virtual Patient Information Update on November 20th at 1:00pm ET. Speakers, topics and other important details will be shared soon - we hope to see you
Lanadelumab (TAKHZYRO), a treatment to routinely prevent attacks in patients with HAE Type I or II who are 12 years old and up, was recently added to Nova Scotia's drug formulary. To access this treatment,
Who is Heather Dow? Heather has been supporting HAE Canada in many ways over the years, from providing technical support for our virtual Patient Information Updates and organizing the AGM, to helping update our strategic
Congratulations to the Canadian HAE Community! Canadians logged the most steps to win the 2021 Global Walk for a third time. Thank you very much to all who participated - the efforts of all illustrate
Happy HAE Day and Happy 10th Anniversary! We hope everyone celebrated HAE Day :-) by doing something extra fun. Did you go for a hike? Did you plant some flowers? Make a special meal for
HAE Canada is happy to share that Saskatchewan is the latest province to add lanadelumab (TAKHZYRO), a subcutaneous preventative HAE treatment, to their provincial drug formulary. Please click here to read the Exceptional Drug Status
We are over the moon that our members are telling us that they are excited about having access to HAEGARDA, a subcutaneous C1 esterase inhibitor (C1-INH) prophylaxis therapy for adolescent and adult HAE patients. We
